FindTrial
Sign In

Effects of pioglitazone on abdominal fat and reactive oxygen species in type 2 diabetes mellitus

Effects of pioglitazone on abdominal fat and reactive oxygen species in type 2 diabetes mellitus - ROSACT

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-C000000441
Enrollment
60
Registered
2006-07-05
Start date
2005-09-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

pioglitazone+diet diet only

Sponsors

Second Department of Internal Medicine, Faculty of Medicine, University of the Ryukyus, Diabetes and Life-style related disease center, Tomishiro Chuo Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Type 2 diabetes mellitus (75g oral glucose tolerance test, ADA criteria) with - male - HbA1c<=7.5%, drug naive - Waist circumference >=85cm - Aged 30-69 years-old - Gave written informed consent

Exclusion criteria

Exclusion criteria: - History of cerebro- and cardio-vascular disease - History of congestive heart failure - History of ketoacidosis or diabetic coma - Moderate to severe liver dysfunction - Moderate to severe renal dysfunction - Moderate to severe infection, before and after operation, severe trauma - Contraindication to antidiabetic medication

Design outcomes

Primary

MeasureTime frame
- Abdominal fat mass - ROS (reactive oxygen species) - Blood lipid parameters—

Secondary

MeasureTime frame
- Glycemic control (OGTT, HbA1c) - Cardiac function - Aortic stiffness (Pulse wave velocity)—

Countries

Japan

Contacts

Public ContactMichio Shimabukuro

Faculty of Medicine, University of the Ryukyus, Okinawa, Japan Second Department of Internal Medicine

mshimabukuro-ur@umin.ac.jp098-895-1146

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026